Navigation Links
Newer Antidepressants May Be Safe for Parkinson's Patients
Date:4/11/2012

By Denise Mann
HealthDay Reporter

WEDNESDAY, April 11 (HealthDay News) -- Some of the newer antidepressants can help treat depression in people with Parkinson's disease without aggravating other disease symptoms such as tremor or rigidity, researchers have found.

Nearly 1 million people in the United States are living with Parkinson's disease, a progressive movement disorder marked by tremor, slowness and/or rigidity. Parkinson's disease and depression tend to travel together, and there has been concern that some of the medications used to treat depression may worsen motor symptoms.

A new study published online April 11 and in the April 17 print issue of Neurology shows that this is not the case, at least when it comes to the antidepressants Paxil (paroxetine) and Effexor (venlafaxine).

Paxil is in the class of drugs known as SSRIs (selective serotonin reuptake inhibitors) while Effexor is an SNRI (serotonin and norepinephrine reuptake inhibitor).

In the new study of 115 people with Parkinson's disease, participants received Paxil, Effexor or an inactive "placebo" pill. The researchers followed-up with patients for 12 weeks and found that both antidepressants improved symptoms of depression without worsening some of the motor symptoms associated with the disease.

On average, those people who took Paxil had a 59 percent improvement and those receiving Effexor had a 52 percent improvement in scores on a standardized tool measuring depression. People who received the placebo had a 32 percent improvement. Three other depression-rating scales showed similar results.

The drugs did not lead to any worsening in motor symptoms, the investigators noted. Use of antidepressants did not improve anxiety levels, thought processes or overall health-related quality of life among the study participants.

Sleep problems were among the most commonly reported side effects. Weight gain was seen with Paxil and at the final study visit, an increase in sitting blood pressure was seen with Effexor, according to the report.

"Depression is the number-one factor negatively affecting the quality of life for people with Parkinson's disease," study author Dr. Irene Hegeman Richard, a neurologist at the University of Rochester Medical Center in Rochester, N.Y., said in a university news release. "It causes a great deal of suffering among patients. The great news here is that it's treatable. And when the depression is treated adequately, many of the other symptoms become much more manageable for patients."

Depression in Parkinson's disease is caused by the underlying disease process, not the stress of dealing with a chronic disease, she said.

Commenting on the study, Dr. Joe Verghese, a neurologist at the Albert Einstein College of Medicine in New York City, said the study provides good news for people with Parkinson's disease and depression. "There is always a concern that we may upset the applecart in Parkinson's by adding a new medication."

Dr. Roy Alcalay, an assistant professor of neurology at Columbia University Medical Center in New York City, agreed that treating depression in Parkinson's disease can be a delicate balance. "The new study validates what we have been doing," he said. "The medications used to treat depression in the general population work as well for Parkinson's disease, and there is no evidence that they have bad side effects on motor symptoms."

While the new study only looked at two antidepressants, "this doesn't mean that others don't work," Alcalay said. As to the robust placebo effect seen in the new study, he said that "just thinking that they are getting treated often helps people with depression."

Treating depression in Parkinson's is important, Alcalay said, and "the study helps us do so in a more educated way."

The U.S. National Institutes of Health/National Institute of Neurological Disorders and Stroke and the Johns Hopkins University School of Medicine funded the study. Wyeth Pharmaceuticals provided Effexor XR and the placebo, while GlaxoSmithKline provided Paxil.

More information

Learn more about Parkinson's disease at the U.S. National Institute of Neurological Disorders and Stroke.

SOURCES: Roy Alcalay, M.D., assistant professor of neurology, Columbia University Medical Center, New York City; Joe Verghese, M.D., neurologist, Albert Einstein School of Medicine, New York City; University of Rochester, news release, April 9, 2012; April 11, 2012, Neurology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Research finds newer radiation therapy technology improves patients quality of life
2. Buildup of Newer Flame Retardants Concerns Scientists
3. FDA Advisers: Newer Forms of the Pill Need Revised Warning Labels
4. FDA Panels to Weigh Safety of Newer Forms of the Pill
5. Newer Blood Thinner May Pose Danger to Trauma Patients
6. Newer Drug Seems Better at Controlling Lupus Kidney Complication
7. Newer Not Necessarily Better for Football Helmet Design
8. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
9. Newer Pill May Raise Blood Clot Risk
10. Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns
11. Are Newer MS Drugs Worth Their High Price Tag?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Antidepressants May Be Safe for Parkinson's Patients
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... According to ... score is invalid because it does not obey the rules Congress has directed the ... equivalent jobs, which the GOP reform would restore. Yet, it estimates a reduction in ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, Cassie ... Litigation seminar in Chicago, Illinois. She will present on: , Filing Benefit ... under ERISA involve claims for long-term disability benefits. This session will address ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... of enhancements, upgrading their training and leads programs. , In February, 2017, Empower ... elite sales agents, Performance Partners is designed to teach how to maximize their ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian ... Bible teacher residing in North Carolina with his wife, Anna Marie. He and his ... six grandchildren. David is also the author of “Shadow and Substance.” , “Love, the ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... to their offering. ... Pain Management in the U.S.: Consumer Strategies ... emphasizing consumer survey analysis, including trends over time. The report ... selected illnesses/conditions strongly associated with physical pain and pain management. ...
(Date:3/24/2017)... YORK , March 24, 2017 FinancialBuzz.com News ... Medical cannabis products ... View Research, Inc., projects that the global medical cannabis market will reach ... is a major market for the new growing industry. By ... place to legally buy and sell medical cannabis. More conservative states like ...
Breaking Medicine Technology: